Jeffrey Chodakewitz
Merck & Co., Inc., Rahway, NJ, USA (United States)
2 papers in the Anchorcite directory, published in 1997, cited 4,613 times in total.
Research topics
- HIV Research and Treatment · 2 papers
- HIV/AIDS drug development and treatment · 2 papers
- HIV-related health complications and treatments · 1 paper
- HIV/AIDS Research and Interventions · 1 paper
Frequent co-authors
- Joseph J. Eron · 2 papers
- Scott M. Hammer · 1 paper
- Kathleen Squires · 1 paper
- Michael D. Hughes · 1 paper
- Janet M. Grimes · 1 paper
- Lisa M. Demeter · 1 paper
- Judith S. Currier · 1 paper
- Judith Feinberg · 1 paper
Papers
- A Controlled Trial of Two Nucleoside Analogues plus Indinavir in Persons with Human Immunodeficiency Virus Infection and CD4 Cell Counts of 200 per Cubic Millimeter or LessNew England Journal of Medicine · 1997 · 2,688 citations
BACKGROUND: The efficacy and safety of adding a protease inhibitor to two nucleoside analogues to treat human immunodeficiency virus type 1 (HIV-1) infection are not clear. We compared treatment with the protease inhibitor indinavir in addition to zidovudine and lamivudine…
- Treatment with Indinavir, Zidovudine, and Lamivudine in Adults with Human Immunodeficiency Virus Infection and Prior Antiretroviral TherapyNew England Journal of Medicine · 1997 · 1,925 citations
BACKGROUND: The new protease inhibitors are potent inhibitors of the human immunodeficiency virus (HIV), and in combination with other antiretroviral drugs they may be able to cause profound and sustained suppression of HIV replication. METHODS: In this double-blind study, 97…
Metadata from OpenAlex (CC0).